The government plans to act against drugmakers with unlisted products. This move aims to stop the sale of irrational fixed-dose combinations. Expert committees suggest unapproved formulations could face license cancellation. Previous government directions failed to ensure lasting compliance with regulations. A new comprehensive framework is now being developed to resolve this issue.